Stocks Health care LTGO
Health careLatigo Biotherapeutics, Inc. (LTGO)
At September 30, 2026 it held $401.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Latigo Biotherapeutics, Inc.
- Net worth
- Latigo Biotherapeutics, Inc. has a market value (market cap) of $844.2M at the latest share price, and shareholders' equity of $394M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
What Latigo Biotherapeutics, Inc. does
Latigo Biotherapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations).
Earnings: every quarter and the next report date
Latest SEC filings
What Latigo Biotherapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Passive stake changed SCHEDULE 13G/A
- November 5, 2026
- November 5, 2026
- October 29, 2026Passive stake (5% or more) SCHEDULE 13G
- September 3, 2026
- September 3, 2026
- August 18, 2026Passive stake (5% or more) SCHEDULE 13G
- August 17, 2026Activist stake (5% or more) SCHEDULE 13D
- August 17, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Latigo Biotherapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 10, 2026 | Sanofi10% owner | Exercised optionsindirect | 494,800 | - |
| August 10, 2026 | Sanofi10% owner | Exercised optionsindirect | 177,978 | - |
| August 10, 2026 | 5AM Ventures VI, L.P.10% owner | Exercised optionsindirect | 4,975,543 | - |
| August 10, 2026 | 5AM Ventures VI, L.P.10% owner | Exercised optionsindirect | 2,350,419 | - |
| August 10, 2026 | Westlake BioPartners Fund I, L.P.10% owner | Exercised optionsindirect | 938,979 | - |
| August 10, 2026 | Westlake BioPartners Fund I, L.P.10% owner | Exercised optionsindirect | 3,547,842 | - |
| August 10, 2026 | Westlake BioPartners Fund I, L.P.10% owner | Exercised optionsindirect | 1,027,635 | - |
| August 10, 2026 | Westlake BioPartners Fund I, L.P.10% owner | Exercised optionsindirect | 3,464,072 | - |
Who owns LTGO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Dr. Beth C. Seidenberg13G, passive with 6 related filers | 19.9% | October 29, 2026 |
| James B. Tananbaum13D, may seek influence with 6 related filers | 14.5% | August 17, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 8.4% | August 17, 2026 |
| Deep Track Capital, LP13G, passive with 2 related filers | 7.03% | August 13, 2026 |
Largest institutional holders
Insiders
6 insiders reported holding 14,041,921 shares in total, about $187.5M at the last price.
| Holder | Shares |
|---|---|
| Tananbaum James B.Director, 10% owner | 3,414,5443,414,544 held indirectly |
| Foresite Capital Management V, LLC10% owner | 3,414,5443,414,544 held indirectly |
| 5AM Ventures VI, L.P.10% owner | 2,350,4192,350,419 held indirectly |
| Seidenberg Beth CDirector, 10% owner | 2,094,8132,094,813 held indirectly |
| Westlake BioPartners Fund I, L.P.10% owner | 2,094,8132,094,813 held indirectly |
| Sanofi10% owner | 672,788672,788 held indirectly |
Questions about LTGO
What does Latigo Biotherapeutics, Inc. do?
Latigo Biotherapeutics, Inc. is a company in the Health care sector.
What is Latigo Biotherapeutics, Inc.'s net worth?
Latigo Biotherapeutics, Inc. has a market value (market cap) of $844.2M at the latest share price, and shareholders' equity of $394M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
When did Latigo Biotherapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 6, 2026.
Similar companies
Compare LTGO with
Follow LTGO
Get an email when Latigo Biotherapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Latigo Biotherapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.